ASPHF
Price
$5.83
Change
+$0.40 (+7.38%)
Updated
Jan 22 closing price
Capitalization
2.2B
NURPF
Price
$7.25
Change
+$0.65 (+9.85%)
Updated
Apr 25 closing price
Capitalization
964.25M
Ad is loading...

ASPHF vs NURPF

Header iconASPHF vs NURPF Comparison
Open Charts ASPHF vs NURPFBanner chart's image
ASCENTAGE PHARMA GROUP
Price$5.83
Change+$0.40 (+7.38%)
Volume$400
Capitalization2.2B
Neuren Pharmaceuticals
Price$7.25
Change+$0.65 (+9.85%)
Volume$100
Capitalization964.25M
ASPHF vs NURPF Comparison Chart
Loading...
View a ticker or compare two or three
VS
ASPHF vs. NURPF commentary
May 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ASPHF is a Buy and NURPF is a Hold.

Ad is loading...
COMPARISON
Comparison
May 02, 2025
Stock price -- (ASPHF: $5.82 vs. NURPF: $7.25)
Brand notoriety: ASPHF and NURPF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ASPHF: 100% vs. NURPF: 7%
Market capitalization -- ASPHF: $2.2B vs. NURPF: $964.25M
ASPHF [@Biotechnology] is valued at $2.2B. NURPF’s [@Biotechnology] market capitalization is $964.25M. The market cap for tickers in the [@Biotechnology] industry ranges from $293.01B to $0. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ASPHF’s FA Score shows that 0 FA rating(s) are green whileNURPF’s FA Score has 1 green FA rating(s).

  • ASPHF’s FA Score: 0 green, 5 red.
  • NURPF’s FA Score: 1 green, 4 red.
According to our system of comparison, NURPF is a better buy in the long-term than ASPHF.

Price Growth

ASPHF (@Biotechnology) experienced а 0.00% price change this week, while NURPF (@Biotechnology) price change was +6.30% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.98%. For the same industry, the average monthly price growth was +8.35%, and the average quarterly price growth was -7.74%.

Industries' Descriptions

@Biotechnology (+2.98% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

FUNDAMENTALS
Fundamentals
ASPHF($2.2B) has a higher market cap than NURPF($964M). ASPHF YTD gains are higher at: 116.543 vs. NURPF (-4.227).
ASPHFNURPFASPHF / NURPF
Capitalization2.2B964M229%
EBITDAN/A108M-
Gain YTD116.543-4.227-2,757%
P/E RatioN/A10.10-
RevenueN/A141M-
Total CashN/AN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
NURPF: Fundamental Ratings
NURPF
OUTLOOK RATING
1..100
78
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
PROFIT vs RISK RATING
1..100
53
SMR RATING
1..100
16
PRICE GROWTH RATING
1..100
63
P/E GROWTH RATING
1..100
86
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
RSI
ODDS (%)
Stochastic
ODDS (%)
Momentum
ODDS (%)
MACD
ODDS (%)
TrendWeek
ODDS (%)
TrendMonth
ODDS (%)
Advances
ODDS (%)
Declines
ODDS (%)
BollingerBands
ODDS (%)
Aroon
ODDS (%)
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GSPRX27.84N/A
N/A
Goldman Sachs Large Cap Equity R
SMVLX70.52N/A
N/A
Smead Value Investor
IUAAX39.72N/A
N/A
VY® Invesco Equity and Income A
TMITX9.71N/A
N/A
Transamerica Mid Cap Growth I3
LOAGX14.60N/A
N/A
Lord Abbett International Growth F3

ASPHF and

Correlation & Price change

A.I.dvisor indicates that over the last year, ASPHF has been loosely correlated with CGEN. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if ASPHF jumps, then CGEN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ASPHF
1D Price
Change %
ASPHF100%
N/A
CGEN - ASPHF
41%
Loosely correlated
+12.14%
CLLS - ASPHF
34%
Loosely correlated
+3.46%
CMVLF - ASPHF
34%
Loosely correlated
N/A
NURPF - ASPHF
30%
Poorly correlated
N/A
ALDX - ASPHF
27%
Poorly correlated
-1.49%
More

NURPF and

Correlation & Price change

A.I.dvisor indicates that over the last year, NURPF has been loosely correlated with CGEN. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if NURPF jumps, then CGEN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NURPF
1D Price
Change %
NURPF100%
N/A
CGEN - NURPF
46%
Loosely correlated
+12.14%
ASPHF - NURPF
30%
Poorly correlated
N/A
SPHRF - NURPF
22%
Poorly correlated
N/A
KRRO - NURPF
21%
Poorly correlated
+5.46%
GDTC - NURPF
21%
Poorly correlated
-0.42%
More